21553-46-8

Usage

Chemical Properties

white to brown crystalline solid

InChI:InChI=1/C10H12O3/c1-6-4-8(10(11)12)5-7(2)9(6)13-3/h4-5H,1-3H3,(H,11,12)/p-1

Upstream product

• 14804-38-7 5-bromo-2-methoxy-1,3-dimethylbenzene 
• 53483-16-2 4-allyl-2,6-dimethylphenyl methyl ether 
• 83037-98-3 (4-methoxy-3,5-dimethylphenyl)methanol 
• 6482-39-9 sodium methyl carbonate 
• 152775-45-6 4-methoxy-3,5-dimethylbenzonitrile 
• 105401-94-3 ethyl 4-methoxy-3,5-dimethylbenzoate 
• 60609-65-6 1-(4-methoxy-3,5-dimethylphenyl)ethanone 

Downstream Products

• 4919-37-3 3,5-dimethyl-4-hydroxybenzoic acid 
• 89686-51-1 2-(4-Methoxy-3,5-dimethyl-phenyl)-3H-imidazo[4,5-c]pyridine; hydrochloride 
• 250609-35-9 (2-benzyl-4,5-dimethyl-thiophen-3-yl)-(4-methoxy-3,5-dimethyl-phenyl)-methanone 
• 1211546-96-1 endo-[3-(4-fluoro-phenyl)-8-aza-bicyclo[3.2.1]oct-8-yl]-(4-methoxy-3,5-dimethyl-phenyl)-methanone 
• 1220708-59-7 N-butyl-5-(4-methoxy-3,5-dimethylphenyl)-1,3,4-thiadiazol-2-amine 
• 1233500-21-4 4-methoxy-3,5-dimethylbenzohydrazide 
• 1350825-70-5 N'-(4-methoxy-3,5-dimethylbenzoyl)-1-methyl-5-phenyl-1H-pyrazole-3-carbohydrazide 
• 1350825-71-6 2-(4-methoxy-3,5-dimethylphenyl)-5-(1-methyl-5-phenyl-1H-pyrazol-3-yl)-1,3,4-oxadiazole 
• 1350825-72-7 2,6-dimethyl-4-(5-(1-methyl-5-phenyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)phenol 
• 70347-05-6 4-methoxy-3,5-dimethylbenzoic acid methyl ester 
• 1381963-43-4 C₃₃H₄₇N₃O₃ 

Relevant academic research and scientific papers

Sodium Methyl Carbonate as an Effective C1 Synthon. Synthesis of Carboxylic Acids, Benzophenones, and Unsymmetrical Ketones

Reported is the synthesis of carboxylic acids, symmetrical ketones, and unsymmetrical ketones with selectivity achieved by exploiting the differential reactivity of sodium methyl carbonate with Grignard and organolithium reagents.

PYRAZOLE DERIVATIVES AS S1P1 AGONISTS

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by sphingosine-1-phosphate receptors (S1P1) agonists.

New pyrazole derivatives

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by sphingosine-1-phosphate receptors (S1P1) agonists.

Anti-aids piperazines

The present invention includes diaromatic substituted heterocyclic compounds (III) STR1 which are useful in treating individuals infected with the HIV virus. The invention includes certain previously generically disclosed anti-AIDS piperazinyl compounds (V) and a method of treating HIV infected individuals with the indoles of formula (V) and the anti-AIDS amines (X).

Steric Enhancement of Resonance-Evidence from Kinetic Study on some Acetophenones

The kinetics of oxidation of some mono-, di- and tri-substituted acetophenones by alkaline hexacyanoferrate(III) in 50percent (v/v) methanol-water mixture at constant ionic strength and at 20, 30 and 40 deg have been studied spectrophotometrically and the rate constants determined by least-squares analysis.Electron-withdrawing groups in the ring facilitate the oxidation of the acetyl function while electron-releasing groups retard the rate.The rate constant values for the oxidation of 3-substituted-4-alkoxy-acetophenones are computed based on the principle of additivity of group effects.The observed rate constants are significantly lower than the calculated values.This is attributed to the phenomenon of steric enhancement of resonance (SER). 3,5-Disubstituted-4-methoxyacetophenones have higher observed rate constant values than the calculated ones.The steric inhibition of resonance (SIR) operates in these systems.In the case of 3-halogeno-4-methoxyacetophenones, the importance of SER increases with increase in the bulkiness of the 3-substituents.The difference between the calculated and observed multiple substituent constants of 3-substituted-4-methoxyacetophenones also lends support for SER.